The efficacy and safety of taxane therapy after discontinuation of nivolumab therapy in Japanese patients with advanced or recurrent esophageal cancer:a retrospective observational study (AFTER NIVO ESO Study)

The efficacy and safety of taxane therapy after discontinuation of nivolumab therapy in Japanese patients with advanced or recurrent esophageal cancer:a retrospective observational study (AFTER NIVO ESO Study) - AFTER NIVO ESO study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042218

Enrollment

Registered

2020-10-23

Start date

2021-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or recurrent esophageal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese patients with advanced/recurrent esophageal cancer who received nivolumab in ATTRACTION-3 and a taxane in the 3rd-line treatment (Paclitaxel or docetaxel) (Patients who started receiving a taxane as a third-line treatment by November 12, 2018)

Exclusion criteria

Exclusion criteria: Patients who withdrew consent before the analysis of this study

Design outcomes

Primary

Measure	Time frame
Response rate of taxanes administered as third-line therapy after nivolumab therapy	—

Secondary

Measure	Time frame
- PFS of taxanes after nivolumab - OS of taxanes after nivolumab - Tumor response rate of target lesions from the start to the end of taxanes treatment - TTF from the start to the end of taxane treatment - Safety of taxanes - PFS from the start of nivolumab treatment to taxane treatment (PFS2) - OS from the start of nivolumab treatment (OS2) - Time from discontinuation of nivolumab treatment to start of taxane treatment (TFS) - Efficacy and safety of taxanes in each subgroup	—

Measure

Time frame

- PFS of taxanes after nivolumab - OS of taxanes after nivolumab - Tumor response rate of target lesions from the start to the end of taxanes treatment - TTF from the start to the end of taxane treatment - Safety of taxanes - PFS from the start of nivolumab treatment to taxane treatment (PFS2) - OS from the start of nivolumab treatment (OS2) - Time from discontinuation of nivolumab treatment to start of taxane treatment (TFS) - Efficacy and safety of taxanes in each subgroup

—

Countries

Japan

Contacts

Public ContactToshiaki Kato

EP-CRSU Co., Ltd Clinical Business Operation Headquarters, Clinical Research Management Center

prj-after_niv@eps.co.jp06-7176-5731

Outcome results